What Illumina Accelerator does

Illumina, Inc. (NASDAQ: ILMN) is a publicly traded Delaware-incorporated corporation headquartered at 5200 Illumina Way, San Diego, that develops next-generation sequencing (NGS) and microarray technologies for genomic analysis. The company's product portfolio spans benchtop-to-production-scale sequencing platforms (MiSeq i100, NextSeq 1000/2000, NovaSeq 6000, NovaSeq X Series), microarray scanners and Infinium arrays, library preparation kits (Illumina DNA Prep, AmpliSeq, Stranded mRNA Prep, Single Cell 3' RNA Prep), and IVD instruments and assays (MiSeqDx, NextSeq 550Dx, VeriSeq NIPT, TruSight Oncology). The technology stack is complemented by a software layer that includes BaseSpace Sequence Hub for cloud data management, DRAGEN for hardware-accelerated secondary analysis, Illumina Connected Analytics/Multiomics/Insights for downstream interpretation, Emedgene for AI-driven variant analysis, and Clarity LIMS for laboratory workflow management.

Illumina operates a multi-channel commercial model combining direct enterprise field sales, inside sales, a global distributor network (including a regional office in Seoul, South Korea), and the MyIllumina e-commerce platform. Revenue is generated through four primary streams: one-time hardware sales of sequencing platforms and microarray scanners, recurring revenue from kits and reagents tied to instrument utilization, software subscriptions and licenses for cloud and on-premise informatics products, and professional services including sequencing services, microarray services, training, and proactive instrument monitoring. Pricing is quote-based and not publicly disclosed, with financing solutions offered to support instrument purchases. The customer base spans oncology research and clinical applications, genetic and rare disease research, reproductive health, microbiology and infectious disease, agrigenomics, and complex disease and population genomics — serving academic research institutions, pharmaceutical companies, clinical laboratories, and commercial agriculture operations globally.

Illumina Accelerator is referenced as a startup accelerator program operated under Illumina, Inc. as part of the parent company's startup ecosystem initiatives; the input data does not provide program-level financials or cohort details. Source data attributes partnerships with IDbyDNA (NGS infectious disease solutions) and Harvard Pilgrim Health Care (value-based NIPT) as core strategic alliances, and notes an active product cadence including the 2026 NovaSeq X Series Software v1.4 and DRAGEN v4.5 release, the Illumina 5-base Solution, and StrataMap Spatial transcriptomics.

Name

Illumina Accelerator

Legal name

Illumina, Inc.

Website

https://illumina.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Illumina, Inc. (NASDAQ: ILMN) develops next-generation sequencing platforms, microarray technologies, library prep kits, and bioinformatics software for genomics research, clinical diagnostics, and applied markets including oncology, rare disease, reproductive health, microbiology, and agrigenomics.

Ownership category

akta.pro rank

Product category

Genomic Sequencing Instruments and Consumables

NAICS

Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210)

SIC

Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)

akta.pro primary industry

Industry/Domain Analytics Solutions & Accelerators (BPAEAHAK)

akta.pro secondary industries

AI/ML Engineering & Model Development Services (BPAEAHAF), Enterprise AI Data & Knowledge Platforms (Vector Databases, Knowledge Graphs) (HDAEANAH)

Keywords

• Genomic sequencing platforms
• Sequencing reagents kits
• Bioinformatics analytics software
• Microarray genotyping solutions
• Genomic data services

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Sequencing Platforms and Instruments: Sale of NGS sequencing platforms ranging from benchtop to production scale systems including NovaSeq X Plus, NextSeq 1000/2000, MiSeq, and microarray scanners. Revenue from one-time hardware sales with ongoing reagent and service requirements.
2. Kits and Reagents: Recurring revenue from library preparation kits, sequencing reagents, microarray kits, and clinical research products. Consumables represent recurring revenue tied to instrument utilization.
3. Software Subscriptions and Licenses: Cloud-based and on-premise software solutions including BaseSpace Sequence Hub, DRAGEN, Illumina Connected Analytics, and Clarity LIMS offered through subscription or perpetual licensing models.
4. Services and Support: Instrument services, training, proactive monitoring, sequencing services, and microarray services provided to customers.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Illumina, Inc. (NASDAQ: ILMN) develops, manufactures, and sells next-generation sequencing (NGS) and microarray-based systems, including benchtop and production-scale sequencers (e.g., NextSeq 2000, MiSeq i100 Series, NovaSeq X), along with associated reagents, library prep kits, microarray consumables, bioinformatics software (Illumina Connected Software/Analytics/Insights), and professional services. The Illumina Accelerator is a startup accelerator program that funds and mentors genomics entrepreneurs building breakthrough applications using Illumina's technology platforms.

Product overview

Illumina offers a comprehensive genomic ecosystem comprising sequencing platforms ranging from benchtop (MiSeq i100 Series) to production scale (NovaSeq X Series, NovaSeq 6000, NextSeq 1000 & 2000), complemented by a full suite of library preparation kits (Illumina DNA Prep, Illumina Stranded mRNA Prep, AmpliSeq, Single Cell 3' RNA Prep) and microarray solutions (Infinium Arrays). The software portfolio centers on BaseSpace Sequence Hub as the cloud data management platform, with DRAGEN for accelerated secondary analysis, and Connected Analytics/Multiomics/Insights for downstream data interpretation and clinical applications. Specialized solutions include TruSight Oncology for cancer testing, TruPath Genome for whole genome sequencing, and Illumina 5-base for combined genetic and epigenetic analysis. The company also provides IVD instruments (MiSeqDx, NextSeq 550Dx) and services including sequencing, microarray, and instrument monitoring. Illumina's technology spans next-generation sequencing, microarray technology, and multiomics integration across genomics, transcriptomics, proteomics, and epigenomics applications.

Differentiator

Problem solved

Functional benefit

Brands

• BaseSpace Sequence Hub: Cloud-based sequencing data analysis platform and software solution
• DRAGEN Secondary Analysis
• Illumina Connected Analytics
• Illumina Connected Multiomics
• Illumina Connected Insights
• Emedgene
• Clarity LIMS
• Infinium Arrays
• AmpliSeq for Illumina
• Illumina DNA Prep
• NovaSeq X Series
• NextSeq 1000 and 2000
• TruSight Oncology
• VeriSeq NIPT Solution
• iHope
• Illumina 5-base Solution
• Illumina StrataMap Spatial
• TruPath Genome Solution

Products and services

• NextSeq 2000 Production-scale next-generation sequencing platform for exomes, transcriptomes, and whole genomes across a broad range of sample types.
• MiSeq i100 Series Benchtop NGS system designed for low-throughput sequencing runs, including targeted panels, amplicon sequencing, small genomes, and 16S metagenomics.
• MiSeq i100 Plus Higher-output benchtop sequencer in the MiSeq i100 family for low- to mid-throughput sequencing applications.
• NextSeq 1000 Mid-throughput NGS platform with P1 and P2 flow cell configurations for a broad range of sequencing applications.
• NextSeq 2000 P4 Higher-throughput configuration of the NextSeq 2000 with P4 flow cells for larger sequencing projects.
• NextSeq 1000 P1 Entry-level flow cell configuration of the NextSeq 1000 sequencing platform.
• NovaSeq X Production-scale sequencing platform delivering high-throughput NGS for large studies and population genomics.
• NovaSeq X Plus Higher-throughput NovaSeq X configuration for very large-scale sequencing projects.
• NovaSeq X 25B High-output flow cell configuration for the NovaSeq X series.
• NovaSeq X 10B Mid-output flow cell configuration for the NovaSeq X series.
• NovaSeq X 1.5B Lower-output flow cell configuration for the NovaSeq X series.
• iSeq 100 Low-throughput benchtop sequencer for targeted and small-scale NGS applications.
• MiSeq Long-running benchtop NGS platform for small genomes, amplicons, and targeted resequencing.
• NextSeq 550 Mid-throughput sequencing and array scanner instrument used for sequencing and cytogenetic analysis.
• NextSeq 2000 Dx IVD-version of the NextSeq 2000 sequencer for clinical diagnostic use.
• NextSeq 550Dx IVD-version of the NextSeq 550 intended for clinical and diagnostic laboratory workflows.
• iScan Microarray scanner used with the Infinium family of genotyping and cytogenetic assays.
• Infinium Microarray Solutions Family of microarray-based assays for genotyping, cytogenetics, and methylation analysis used on the iScan system.
• Illumina Connected Software Suite of bioinformatics software including BaseSpace Sequence Hub and related tools for run planning, analysis, and data management.
• Illumina Connected Analytics Cloud-based analytics environment for processing and interpreting NGS data at scale.
• Illumina Connected Insights Software suite supporting variant interpretation and genomic insights for clinical and translational workflows.
• Illumina Proactive Instrument performance monitoring service that enables remote support and uptime optimization for sequencing systems.
• Illumina Professional Services Consulting and expert services supporting sequencing program design, lab setup, and data interpretation.
• Illumina Training Educational and certification programs that train scientists and lab staff on Illumina sequencing and analysis workflows.
• Illumina Accelerator Startup accelerator program operated by Illumina that invests in and mentors genomics entrepreneurs building applications on Illumina technology; typically concludes with a public pitch event.

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• IDbyDNAcoreTechnology or IntegrationPartnership to deliver NGS infectious disease solutions combining Illumina sequencing technology with IDbyDNA's advanced molecular diagnostics capabilities for comprehensive pathogen detection and characterization.
• Harvard Pilgrim Health CarecoreStrategic or Co-development PartnerFirst NGS agreement for Non-Invasive Prenatal Testing (NIPT) establishing value-based healthcare partnership for genomic testing services.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Bio-Rad Laboratories: Life sciences tools provider with droplet digital PCR, qPCR, and clinical diagnostics; overlaps with Illumina in research instruments and selected clinical applications.
• Thermo Fisher Scientific: Largest life sciences tools company offering sequencing (Ion Torrent), reagents, qPCR, and clinical diagnostics instruments. Competes with Illumina across reagents, instruments, and clinical genomics, though Illumina remains the NGS leader.
• Qiagen: Sample-prep, molecular diagnostics, and bioinformatics provider; overlaps with Illumina on nucleic acid extraction, library prep reagents, and clinical bioinformatics.
• Roche: Diagnostics giant with a growing NGS and digital PCR portfolio (KAPA reagents, AVENIO ctDNA, Navify); overlaps with Illumina in clinical oncology and reproductive health.
• Danaher: Diversified life sciences conglomerate owning Beckman Coulter, Cepheid, Leica, and IDT — competing with Illumina across reagents, sample prep, and diagnostics-adjacent workflows.
• Agilent Technologies: Life sciences and diagnostics company offering microarrays, NGS target enrichment (SureSelect), and bioinformatics; competes with Illumina in microarrays and selected sequencing workflows.

Direct peers

• Pacific Biosciences: Long-read sequencing platform (Revio, Sequel II) increasingly competing in whole-genome, clinical, and complex-genome applications where Illumina's short reads have limitations.
• Oxford Nanopore Technologies: Nanopore-based long-read sequencing (MinION, PromethION) competing across research and clinical genomics; a credible alternative for applications requiring long reads or rapid in-field sequencing.
• BGI Group / MGI Tech: Chinese genomics conglomerate offering DNBSEQ sequencing platforms and reagents at lower price points; competes globally on cost and is the primary IP-dispute counterpart to Illumina.
• 10x Genomics: Single-cell and spatial genomics company (Chromium, Visium/Xenium); partners with Illumina sequencers and increasingly competes for high-value multi-omics and spatial workflows now addressed by StrataMap Spatial.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/illumina
• Facebookfacebook.com/illuminainc
• LinkedInlinkedin.com/company/illumina-accelerator
• Instagraminstagram.com/illuminainc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments41 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Illumina Accelerator